Loading company…
ID 406339859 · FY 2023–2024 · 2 years
ძირითად საქმიანობას წარმოადგენს მედიკამენტების და ბიოლოგიურად აქტიური დანამატების იმპორტი და საბითუმო რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2023 | 2024 | CAGR |
|---|---|---|---|
| Total Revenue | 2,017 | 3,614 | +79.2% |
| Total COGS | -1,649 | -2,604 | +57.9% |
| Gross Profit | 368 | 1,011 | +174.9% |
| Gross Margin | 18.2% | 28.0% | |
| Total Operating Expenses | -505 | -979 | +93.8% |
| EBITDA | -137 | 32 | nmf |
| EBITDA Margin | -6.8% | 0.9% | |
| Total D&A | 0 | -2 | |
| EBIT / Operating Income | -137 | 30 | nmf |
| Total Other Income | -15 | -43 | +187.7% |
| Profit Before Tax | -152 | -13 | -91.6% |
| Total Income Tax | -0 | -0 | +827.3% |
| Net Profit / (Loss) | -152 | -13 | -91.6% |
| Net Margin | -7.6% | -0.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.